Ähnliche Meldungen
Meghalaya Launches Homestay Subsidy Scheme for National Games 2027
Meghalaya's government launched a homestay subsidy scheme, offering up to 70% support, to boost accommodation for the National Games 2027 and foster long-term community-owned tourism. The initiative aims to address temporary housing needs while creating entrepreneurship and livelihoods.
Adani Power Q1 net profit up 42% to Rs 4,806 crore; board approves Rs 15,000 crore fundraising
Adani Power reported a 42% year-on-year increase in consolidated net profit to Rs 4,806 crore in Q1, with revenue growing 34% to Rs 18,902 crore. The company's board also approved a fundraising of Rs 15,000 crore, driven by rising power demand and higher capacity utilization.
Gold Rates Today: Significant Increase Across Leading Indian Jewellery Brands on July 22, 2026
Gold rates significantly increased across major Indian jewellery brands like Tanishq, Malabar Gold & Diamonds, and Joyalukkas on July 22, 2026. Prices for 22k gold rose, influenced by technical buying, escalating Middle East conflict, and anticipation of the Fed meeting.
Indian Taxpayers with Global Income Face Double Taxation Concerns
Indian Resident and Ordinarily Resident (ROR) taxpayers earning global income face potential double taxation. India's Double Taxation Avoidance Agreements (DTAAs) offer relief through tax credits or exclusive taxing rights, but accurate reporting of foreign income and assets is crucial for compliance and avoiding unnecessary tax burdens.
Choosing the Right Income Tax Return Form for AY 2026-27: A Comprehensive Guide
For AY 2026-27, individuals must select the correct ITR form based on income sources like salary, house property, business, capital gains, and other sources. ITR-1 now allows reporting up to two house properties under specific conditions, while ITR-3 or ITR-4 are for business income, and ITR-2 for complex income without business profits.
US Tariffs on Generic Drugs: India's Pharma Exporters Face Challenge, Cost Advantage May Help
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could pressure Indian pharmaceutical exporters, but India's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).